Bisphosphonates help prevent progressive bone mineralization loss and subsequent osteoporotic fractures. However, long-term bisphosphonate therapy paradoxically increases the risk of a unique injury called an atypical subtrochanteric femur fracture. Despite this, the benefits of bisphosphonates outweigh the risks, because far more pathologic fractures are prevented than induced. The early identification of atypical subtrochanteric femur fractures is important as there is high associated morbidity and mortality. We describe a case of a 76-y-old woman with a completed bisphosphonate-associated atypical subtrochanteric femur fracture.
Long-t erm bisphosphonate therapy is associated with an increased risk of atypical femoral fractures. Early identification and intervention is essential to avoid the associated morbidity and mortality of a completed fracture.
CASE REPORT
A 76-y-old woman presented with severe, atraumatic, right hip and thigh pain. She reported a history of osteopenia treated with bisphosphonates (nearly 4 y of alendronate, followed by 4 y of ibandronate). Femur radiographs at presentation were read as normal but on retrospect demonstrated focal cortical thickening along the lateral diaphysis ( ½Fig: 1 Fig. 1 ). A bone scan 5 d later showed focal radiotracer uptake at the same site, interpreted as concerning for an atypical subtrochanteric femur fracture ( ½Fig: 2 Fig. 2 ). Six days later, the patient re-presented with increasing pain after a fall from standing. Repeated radiographs showed a displaced transverse fracture through the proximal right femoral diaphysis ( ½Fig: 3 Fig. 3 ).
DISCUSSION
Osteoporosis places individuals at high risk for insufficiency and fragility fractures. Treatment includes lifestyle modifications and pharmacologic intervention, frequently with bisphosphonates (1).
Bisphosphonates work by inducing osteoclast apoptosis (2, 3) . A known risk of long-term bisphosphonate therapy is a unique fracture known as an atypical subtrochanteric femur fracture. These may result from impaired remodeling allowing microfractures to progress (4) . A 2008 study of the entire population of Sweden reported an age-adjusted relative risk of atypical femur fracture with any bisphosphonate use of 47.3, corresponding to an additional 5 cases per 10,000 patient-years (5). Multiple additional epidemiologic studies showed a patient on bisphosphonates had a relative risk of atypical femur fracture ranging from 2.11 to 66.9, although the absolute risk remains low (4). These fractures have a mortality rate of 14% at 12 mo and 25% at 24 mo (6) .
The American Society for Bone and Mineral Research task force recommended a fracture must be located distal to the lesser trochanter to just proximal to the supracondylar flare and have 4 of these 5 major features to be classified as atypical: (1) no or minimal associated trauma, as in a fall from standing; (2) the fracture line originating at the lateral cortex, substantially transverse in its orientation; (3) complete fractures involving both cortices (may be associated with a medial spike) or incomplete fractures involving only the lateral cortex; (4) noncomminuted or minimally comminuted; and (5) localized periosteal or endosteal thickening of the lateral cortex is present (4). On bone scanning, there will be focal increased radiotracer activity corresponding to the area of cortical thickening (7) .
Early diagnosis of incomplete fractures helps prevent completion by allowing for prophylactic operative management (4).
CONCLUSION
Although bisphosphonate therapy prevents far more osteoporotic fractures than it induces atypical fractures, atypical subtrochanteric fractures have high morbidity and mortality. Thus, early recognition is necessary to allow for appropriate protective operative intervention.
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